Clinical trial
CHOICES: A Randomized Phase II Trial of Imatinib (IM) Versus Hydroxychloroquine (HCQ) and IM for Patients With Chronic Myeloid Leukemia (CML) in Major Cytogenetic Response (MCyR) With Residual Disease Detectable by Quantitative Polymerase Chain Reaction (Q-PCR).
NCT01227135 is registered in ClinicalTrials.gov with Lynn McMahon as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- CHOICES: A Randomized Phase II Trial of Imatinib (IM) Versus Hydroxychloroquine (HCQ) and IM for Patients With Chronic Myeloid Leukemia (CML) in Major Cytogenetic Response (MCyR) With Residual Disease Detectable by Quantitative Polymerase Chain Reaction (Q-PCR).
- Lead sponsor
- Lynn McMahon
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- March 31, 2010
- Completion date
- Not reported
- Enrollment
- 66 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.